A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate...
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
About this item
Full title
Author / Creator
Publisher
United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Journal title
Language
English
Formats
Publication information
Publisher
United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subjects
More information
Scope and Contents
Contents
To assess the safety and efficacy of brodalumab, a human anti-interleukin-17 receptor monoclonal antibody, in patients with moderate-to-severe Crohn's disease (CD).
Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study in patients with moderate-to-severe CD and evidence of active inflammation. Patients were randomized 1:1:1:1...
Alternative Titles
Full title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1846399164
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1846399164
Other Identifiers
ISSN
0002-9270
E-ISSN
1572-0241
DOI
10.1038/ajg.2016.298
